Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175): appraisal consultation 3
This page was last updated: 13 August 2014
|Closing date for invited submissions / evidence submission:||9 July 2013|
|1st appraisal committee meeting:||07 January 2013|
|2nd appraisal committee meeting:||05 March 2014|
|3rd appraisal committee meeting:||08 July 2014|
|Technical Lead:||Martyn Burke|
|Communications manager:||Alice Law|
An error has recently been identified in the economic model used to inform the Appraisal Committee’s decision making. This may or may not have a material effect on the Committee’s recommendations detailed in the second Appraisal Consultation Document (ACD), out for consultation.
In light of the above, NICE has taken the decision to stop the consultation on the ACD. An addendum to the Assessment Report explaining the error and presenting the impact on cost-effectiveness results will be prepared. NICE will then consult with consultees and commentators on this addendum, before any further Committee discussion.
The next Committee discussion planned for 7 May 2014 has therefore been cancelled. We are currently arranging the next steps and timelines for this appraisal